Compare uniQure N.V. Ordinary Shares (QURE) vs Sea Limited (SE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
uniQure N.V. Ordinary Shares vs Sea Limited — how do they compare? uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B), while Sea Limited trades at $94 (market cap $58.76B). The key difference: Sea Limited is far larger — about 39.7× uniQure N.V. Ordinary Shares's market cap, and Sea Limited is more actively traded (5,236,560 versus 2,488,780). Which is the better fit depends on your goals — on Pluang, investors hold uniQure N.V. Ordinary Shares for 0 Days and Sea Limited for 103 Days on average.
| QURE | SE | |
|---|---|---|
Market Cap | $1.48B | $58.76B |
Volume | 2,488,780 | 5,236,560 |
Sector | Health | Consumer Cyclical |
52-Week High | $70.59 | $165.70 |
52-Week Low | $9.03 | $78.16 |
Typical Hold Time | 0 Days | 103 Days |
Enterprise Value | $728.62M | $53.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Sea Limited (SE) trades at $95.31, down 0.59% with a bearish technical signal. The company shows strong revenue growth from $22.94B in 2025 to projected $27.7B in 2026, with net income reaching $1.58B. Recent earnings show mixed results with Q4 2025 missing estimates but Q1 and Q2 2026 beating expectations. Analyst consensus remains strongly bullish with 72.7% buy ratings and a $153.67 price target, representing 61% upside potential from current levels.
The investment case hinges on continued e-commerce and fintech growth despite recent stock weakness. Key risks include margin compression concerns and insider selling activity. Positive cash flow generation since 2025 and improving profitability metrics support the bullish analyst outlook, though technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About uniQure N.V. Ordinary Shares
uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →About Sea Limited
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →
